Arecco, L.; Bruzzone, M.; Bas, R.; Kim, H. J.; Di Meglio, A.; Bernstein-Molho, R.; Hilbers, F. S.; Pogoda, K.; Carrasco, E.; Punie, K.; Bajpai, J.; Agostinetto, E.; Lopetegui-Lia, N.; Partridge, A. H.; Phillips, K. A.; Toss, A.; Rousset-Jablonski, C.; Curigliano, G.; Renaud, T.; Ferrari, A.; Paluch-Shimon, S.; Fruscio, R.; Cui, W.; Wong, S. M.; Vernieri, C.; Couch, F. J.; Dieci, M. V.; Matikas, A.; Rozenblit, M.; Mendez, D. Aguilar-y; De Marchis, L.; Puglisi, F.; Fabi, A.; Graff, S. L.; Witzel, I.; Hernandez, A. Rodriguez; Fontana, A.; Pesce, R.; Duchnowska, R.; Pais, H. L.; Sini, V.; Sokolovic, E.; de Azambuja, E.; Ceppi, M.; Blondeauxt, E.; Lambertini, M.

Real-world treatment patterns and outcomes in patients with HRD/HER2L metastatic breast cancer treated with chemotherapy in the United States

ESMO OPEN

IF8.3

2024-09-012

OAAI

Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study Editoral Comment

OBSTETRICAL & GYNECOLOGICAL SURVEY

IF3.6

2024-08-010

Lambertini, Matteo; Blondeaux, Eva; Agostinetto, Elisa; Hamy, Anne-Sophie; Kim, Hee Jeong; Di Meglio, Antonio; Molho, Rinat Bernstein; Hilbers, Florentine; Pogoda, Katarzyna; Carrasco, Estela; Punie, Kevin; Bajpai, Jyoti; Ignatiadis, Michail; Moore, Halle C. F.; Phillips, Kelly-Anne; Toss, Angela; Rousset-Jablonski, Christine; Peccatori, Fedro A.; Renaud, Tiphaine; Ferrari, Alberta; Paluch-Shimon, Shani; Fruscio, Robert; Cui, Wanda; Wong, Stephanie M.; Vernieri, Claudio; Ruddy, Kathryn J.; Dieci, Maria Vittoria; Matikas, Alexios; Rozenblit, Mariya; Villarreal-Garza, Cynthia; de Marchis, Laura; del Mastro, Lucia; Puglisi, Fabio; Estevez-Diz, Maria del Pilar; Rodriguez-Wallberg, Kenny A.; Mrinakova, Bela; Meister, Sarah; Livraghi, Luca; Clatot, Florian; Yerushalmi, Rinat; de Angelis, Carmine; Sanchez-Bayona, Rodrigo; Meattini, Icro; Cichowska-Cwalinska, Natalia; Berliere, Martine; Salama, Mahmoud; de Giorgi, Ugo; Sonnenblick, Amir; Chiodi, Camila; Lee, Young-Jin; Maria, Camille; Azim Jr, Hatem A.; Boni, Luca; Partridge, Ann H.

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer (vol 10, 33, 2024)

NPJ BREAST CANCER

IF7.6

2024-07-091

OAAI

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (vol 8, 98, 2022)

sacituzumab govitecan治疗转移性三阴性乳腺癌的3期ASCENT试验的安全性分析 (第8、98、2022卷)

NPJ BREAST CANCER

IF7.6

2024-06-060

OAAI

Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review

BREAST CANCER RESEARCH

IF5.6

2024-05-223

OAAI

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

CANCER

IF5.1

2024-05-166

OAAI

Schettini, Francesco; Blondeaux, Eva; Molinelli, Chiara; Bas, Raphaelle; Kim, Hee Jeong; Di Meglio, Antonio; Bernstein Molho, Rinat; Linn, Sabine C.; Pogoda, Katarzyna; Carrasco, Estela; Punie, Kevin; Agostinetto, Elisa; Lopetegui-Lia, Nerea; Phillips, Kelly-Anne; Toss, Angela; Rousset-Jablonski, Christine; Acheritogaray, Marion; Ferrari, Alberta; Paluch-Shimon, Shani; Fruscio, Robert; Cui, Wanda; Wong, Stephanie M.; Vernieri, Claudio; Dieci, Maria Vittoria; Matikas, Alexios; Rozenblit, Mariya; Villarreal-Garza, Cynthia; De Marchis, Laura; Puglisi, Fabio; Vasconcelos de Matos, Leonor; Marino, Monica; Teixeira, Luis; Graffeo, Rossella; Rognone, Alessia; Chirco, Alessandra; Antone, Nicoleta; Abdou, Yara; Marhold, Maximilian; Bozovic-Spasojevic, Ivana; Cortes Salgado, Alfonso; Carmisciano, Luca; Bruzzone, Marco; Curigliano, Giuseppe; Prat, Aleix; Lambertini, Matteo

Efficacy and Safety of Alpelisib in PIK3CAmutated, hormone receptorpositive advanced breast cancer after a CDK4/6 inhibitor: An Openlabel, Multi-centre, Prospective, Single Arm Clinical Trial

CANCER RESEARCH

IF16.6

2024-05-020

PRE

ASCENT-07: A phase 3, randomized, open-label study of sacituzumab govitecan versus treatment of physician's choice in patients with HR+/HER2-inoperable, locally advanced, or metastatic breast cancer post-endocrine therapy

CANCER RESEARCH

IF16.6

2024-05-021

PRE

Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N plus carboplatin plus paclitaxel (CbP) vs concurrent N plus CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N)

CANCER RESEARCH